Neurology

The Biology of ADAR1: An Overactive 'False Alarm'

At a Glance

ADAR-related hereditary spastic paraplegia can result when ADAR1 variants impair RNA editing, causing the immune system to mistake the body's own RNA for a virus. This may keep interferon signaling active and contribute to spasticity, walking difficulties, and other findings.

To understand ADAR-related Hereditary Spastic Paraplegia (HSP), it helps to look at how your body distinguishes between itself and a virus. Most forms of HSP are caused by diverse mechanisms—often problems with the “plumbing” of nerve cells, how they transport fuel, or lipid metabolism ^[1]^[2]. ADAR-related HSP is different; it is a disorder that involves abnormal innate-immune signaling (an immune “false alarm”) in addition to neural and cell-intrinsic RNA-editing effects ^[3].

The Role of ADAR1: The ‘Self’ Editor

Every cell in your body contains RNA. Sometimes, your own RNA can fold into a shape called double-stranded RNA (dsRNA). Interestingly, many viruses also use dsRNA when they invade your cells ^[4]. To prevent your immune system from accidentally attacking your own RNA, your body uses a protein called ADAR1 ^[5].

ADAR1 performs a process called RNA editing. it travels along your RNA and converts a chemical called adenosine into inosine (A-to-I editing) ^[5]. This change acts like a “passport stamp,” telling your immune system: “This RNA belongs here; do not attack” ^[4]^[6].

The Biological ‘False Alarm’

When the ADAR1 gene has a mutation, it cannot “stamp” the RNA correctly. Your immune system sees this unedited RNA and mistakes it for a viral infection ^[7]. This triggers a specific alarm system called the MDA5-MAVS pathway ^[3].

Once this alarm is pulled, the body begins producing high levels of Type I Interferon ^[8]. Interferon is a powerful chemical usually reserved for fighting off the flu or other viruses. In ADAR-related conditions, however, the interferon “faucet” can become stuck in the “on” position, leading to chronic inflammation. This state is known as an interferonopathy ^[9].

Genetics: One Copy vs. Two

The way this condition shows up in your life often depends on the specific variant and how many copies of the mutated gene you have:

Biallelic (Two copies): Having two mutations (one from each parent) is commonly associated with Aicardi-Goutières Syndrome Type 6 (AGS6), a more severe condition that starts in infancy, though severity varies ^[10].
Heterozygous (One copy): Having just one mutation usually causes Dyschromatosis Symmetrica Hereditaria (DSH), which primarily affects skin pigment but can have neurologic manifestations ^[11]^[12].

The c.3019G>A Exception

There is a very specific mutation, known as c.3019G>A (or p.Gly1007Arg), that has been reported with a broader neurologic phenotype. Even if you have only one copy of this specific mutation, it has been associated with the spasticity and walking difficulties typical of HSP ^[13]. Research shows this specific change is still being characterized, but it strongly impairs the protein’s ability to edit RNA, causing a significant immune false alarm even when a healthy copy of the gene is present ^[14].

ADAR-HSP vs. ‘Typical’ HSP

It is important to recognize that ADAR-related HSP is biologically unique compared to other types of HSP:

Feature	Typical HSP (e.g., SPG4, SPG3A)	ADAR-Related HSP
Primary Cause	Diverse mechanisms, often involving axonal transport or cell “plumbing” ^[1]	RNA-editing defects and abnormal innate-immune signaling ^[9]
Main Target	Long nerve fibers in the spinal cord ^[2]	Brain, spinal cord, and sometimes skin/organs depending on the phenotype ^[15]
Mechanism	Axon degradation and varied cellular stress ^[1]	Inflammation via the MDA5 pathway and neural effects ^[3]

Because ADAR-related HSP involves abnormal immune signaling, your doctors may look at experimental treatments designed to manage the body’s internal “false alarm.” However, it is crucial to note that suppressing interferon signaling does not guarantee that established neurological injury will be reversed ^[16].

Common questions in this guide

What does ADAR1 normally do in the body?

ADAR1 edits certain double-stranded RNA by changing adenosine to inosine. This editing helps the immune system recognize the RNA as part of the body rather than mistaking it for viral material.

How can an ADAR1 mutation cause an immune false alarm?

When ADAR1 does not edit RNA correctly, the MDA5-MAVS pathway can treat the RNA as a viral signal. This can raise type I interferon levels and keep inflammation active, a pattern called an interferonopathy.

What is the difference between one and two ADAR1 gene variants?

Two altered copies are commonly linked with Aicardi-Goutières syndrome type 6, which often begins in infancy and can be severe, although severity varies. One altered copy usually causes dyschromatosis symmetrica hereditaria, but certain variants, including c.3019G>A, have been linked with neurological problems such as spasticity and walking difficulty.

What does the c.3019G>A ADAR1 variant mean for HSP?

The c.3019G>A variant, also called p.Gly1007Arg, has been associated with HSP-like spasticity and walking difficulties even when only one copy is altered. Researchers are still defining its full range of effects, so a genetics professional should interpret the result alongside your clinical findings.

Could ADAR-related HSP affect more than the nervous system?

It can. Depending on the genetic variant and phenotype, ADAR-related conditions may also involve skin or other organs; skin pigment changes and light-and-dark spots on the hands and feet can occur. The presence and extent of these findings vary between people.

Can lowering interferon signaling repair neurological damage?

Treatments that reduce interferon signaling are being considered or studied for the immune overactivity in ADAR-related conditions. Lowering the signal may not reverse neurological injury that has already occurred, so treatment decisions require specialist assessment.

What can an interferon signature blood test tell me?

An interferon signature test may help show whether interferon-related immune signaling is currently elevated. Its usefulness and interpretation depend on your symptoms, genetic result, and clinical context, so ask your care team whether it would change monitoring or treatment.

Get notified when new evidence is published on ADAR-related hereditary spastic paraplegia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (16)

1
Hereditary spastic paraplegia.
Blackstone C
Handbook of clinical neurology 2018; (148()):633-652 doi:10.1016/B978-0-444-64076-5.00041-7.
PMID: 29478605
2
Converging cellular themes for the hereditary spastic paraplegias.
Blackstone C
Current opinion in neurobiology 2018; (51()):139-146 doi:10.1016/j.conb.2018.04.025.
PMID: 29753924
3
ADAR1 interaction with Z-RNA promotes editing of endogenous double-stranded RNA and prevents MDA5-dependent immune activation.
de Reuver R, Dierick E, Wiernicki B, et al.
Cell reports 2021; (36(6)):109500 doi:10.1016/j.celrep.2021.109500.
PMID: 34380029
4
RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself.
Liddicoat BJ, Piskol R, Chalk AM, et al.
Science (New York, N.Y.) 2015; (349(6252)):1115-20 doi:10.1126/science.aac7049.
PMID: 26275108
5
Adenosine Deaminases Acting on RNA (ADARs) and Viral Infections.
Pfaller CK, George CX, Samuel CE
Annual review of virology 2021; (8(1)):239-264 doi:10.1146/annurev-virology-091919-065320.
PMID: 33882257
6
Identification of ADAR1 p150 and p110 Associated Edit Sites.
Sun T, Rosenberg BR, Chung H, Rice CM
Methods in molecular biology (Clifton, N.J.) 2023; (2651()):285-294 doi:10.1007/978-1-0716-3084-6_20.
PMID: 36892775
7
Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown.
Chung H, Calis JJA, Wu X, et al.
Cell 2018; (172(4)):811-824.e14 doi:10.1016/j.cell.2017.12.038.
PMID: 29395325
8
The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways.
Nakahama T, Kawahara Y
International immunology 2023; (35(3)):123-133 doi:10.1093/intimm/dxac056.
PMID: 36469491
9
ADAR RNA Modifications, the Epitranscriptome and Innate Immunity.
Quin J, Sedmík J, Vukić D, et al.
Trends in biochemical sciences 2021; (46(9)):758-771 doi:10.1016/j.tibs.2021.02.002.
PMID: 33736931
10
Bilateral striatal necrosis caused by ADAR mutations in two siblings with dystonia and freckles-like skin changes that should be differentiated from Leigh syndrome.
Piekutowska-Abramczuk D, Mierzewska H, Bekiesińska-Figatowska M, et al.
Folia neuropathologica 2016; (54(4)):405-409 doi:10.5114/fn.2016.64819.
PMID: 28139822
11
Case Report: Aicardi-Goutières Syndrome Type 6 and Dyschromatosis Symmetrica Hereditaria With Congenital Heart Disease and Mitral Valve Calcification - Phenotypic Variants Caused by Adenosine Deaminase Acting on the RNA 1 Gene Homozygous Mutations.
Liu L, Zhang L, Huang P, et al.
Frontiers in pediatrics 2022; (10()):852903 doi:10.3389/fped.2022.852903.
PMID: 35832578
12
Genetic spectrum of dyschromatosis symmetrica hereditaria in Chinese patients including a novel nonstop mutation in ADAR1 gene.
Zhang G, Shao M, Li Z, et al.
BMC medical genetics 2016; (17()):14 doi:10.1186/s12881-015-0255-1.
PMID: 26892242
13
Autosomal dominant ADAR c.3019G>A (p.(G1007R)) variant is an important mimic of hereditary spastic paraplegia and cerebral palsy.
Jones HF, Stoll M, Ho G, et al.
Brain & development 2022; (44(2)):153-160 doi:10.1016/j.braindev.2021.10.001.
PMID: 34702576
14
Impact of Disease-Associated Mutations on the Deaminase Activity of ADAR1.
Karki A, Campbell KB, Mozumder S, et al.
Biochemistry 2024; (63(3)):282-293 doi:10.1021/acs.biochem.3c00405.
PMID: 38190734
15
Co-occurrence of Aicardi-Goutières syndrome type 6 and dyschromatosis symmetrica hereditaria due to compound heterozygous pathogenic variants in ADAR1: a case series from India.
Sathishkumar D, Muthusamy K, Gupta A, et al.
Clinical and experimental dermatology 2021; (46(4)):704-709 doi:10.1111/ced.14531.
PMID: 33289110
16
Aberrant multicellular interferon signaling underlies Adar1 mutation-driven Aicardi-Goutières syndrome-like encephalopathy.
Yoo H, Nakahama T, Sugihara R, et al.
Cell reports 2026; (45(4)):117113 doi:10.1016/j.celrep.2026.117113.
PMID: 41855203

This page explains ADAR1 biology and interferon signaling for informational purposes only and does not constitute medical advice. A neurologist or genetics professional should interpret your variant, test results, and treatment options.